{"organizations": [], "uuid": "cff9066bf901dcbf270aa19a4849fd2615db6a58", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/bristol-myers-study/bristol-myers-says-cancer-drug-combo-reduces-death-risk-idUSL3N1RT4T3", "country": "US", "domain_rank": 408, "title": "Bristol-Myers says cancer drug combo reduces death risk", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-04-16T16:24:00.000+03:00", "replies_count": 0, "uuid": "cff9066bf901dcbf270aa19a4849fd2615db6a58"}, "author": "", "url": "https://www.reuters.com/article/bristol-myers-study/bristol-myers-says-cancer-drug-combo-reduces-death-risk-idUSL3N1RT4T3", "ord_in_thread": 0, "title": "Bristol-Myers says cancer drug combo reduces death risk", "locations": [], "entities": {"persons": [{"name": "manas mishra", "sentiment": "none"}, {"name": "keytruda", "sentiment": "none"}, {"name": "anil d’silva", "sentiment": "none"}, {"name": "yervoy", "sentiment": "none"}], "locations": [{"name": "bengaluru", "sentiment": "none"}, {"name": "opdivo", "sentiment": "none"}], "organizations": [{"name": "bristol-myers squibb", "sentiment": "none"}, {"name": "merck & co", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 16, 2018 / 1:26 PM / Updated 11 minutes ago Bristol-Myers says cancer drug combo reduces death risk Reuters Staff 1 Min Read \nApril 16 (Reuters) - Bristol-Myers Squibb said on Monday its cancer drugs, Opdivo and Yervoy, reduced the risk of the disease spreading or death in previously untreated patients with a type of lung cancer. \nThe combination demonstrated a higher rate of progression-free survival, compared with chemotherapy in a late-stage trial, the company said. \nThe results come a week after rival Merck & Co said a trial testing its blockbuster drug Keytruda as a monotherapy in previously untreated lung cancer patients was successful. (Reporting by Manas Mishra in Bengaluru; Editing by Anil D’Silva)", "external_links": [], "published": "2018-04-16T16:24:00.000+03:00", "crawled": "2018-04-16T16:43:47.004+03:00", "highlightTitle": ""}